Front Row Advisors’s DexCom DXCM Stock Holding History

Front Row Advisors’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-1,584	Closed	-$23K	–	953
2017 Q4	$23K	Buy	+1,584	New	+$20.6K	0.02%	322

Other funds holding DXCM

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Front Row Advisors's DXCM Position: Q1 2018 in Review

Front Row Advisors sold out of DexCom (DXCM) in Q1 2018, closing a stake of 1,584 shares — an estimated $23K sold.

Front Row Advisors first reported a position in DXCM in Q4 2017 and held it in 1 quarter. The position peaked at $23K in Q4 2017. 276 funds tracked by Wall St. Rank hold DXCM as of Q1 2018.

Front Row Advisors reported no remaining DexCom position as of Q1 2018 after selling out during the quarter.
Front Row Advisors sold 1,584 DexCom shares in Q1 2018, an estimated $23K.
Front Row Advisors first reported a position in DexCom in Q4 2017 and held it in 1 quarter.
Front Row Advisors's DexCom position peaked at $23K in Q4 2017.
276 funds tracked by Wall St. Rank held DexCom as of Q1 2018.

Based on Front Row Advisors's 13F filing for Q1 2018, filed 21 May 2018.